Patents by Inventor Guy Brusselle

Guy Brusselle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of reslizumab to treat moderate to severe eosinophilic asthma
    Patent number: 10577414
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 3, 2020
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Use of Reslizumab to Treat Moderate to Severe Eosinophilic Asthma
    Publication number: 20180030131
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Christopher Obrien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Use of Reslizumab To Treat Moderate to Severe Eosinophilic Asthma
    Publication number: 20160102144
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L; and 2) administering to said patient a therapeutically effective dose of reslizumab.
    Type: Application
    Filed: August 28, 2015
    Publication date: April 14, 2016
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle